Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

In This Issue

In This Issue OPTOMETRY AND VISION SCIENCE Copyright © 2013 American Academy of Optometry • Challenges to and colleagues. Five pharmaceutical industry–funded Implementation of an laboratories across Canada were included in a validation Epidermal Growth Factor and quality control exercise for the EGFR test. Patients with Receptor Testing Strategy nonsquamous lung cancer were enrolled online, where basic for Non–Small-Cell Lung demographics and decision on gefinitib prescription were Cancer in a Publicly Funded Health Care recorded. Of the 2104 requests for EGFR mutation testing, System 84% were fulfilled, with a median turnaround time of 18 days. The majority of the requests were for adenocarcinoma and stage IV disease, 58% women, 41% light/never smokers, and 13.9% Asians. Among patients tested for EGFR mutation, 17% were prescribed with gefitinib. The number of tests requested each month dropped from 200–250 to 50–100 after the initial 12 months, funded In this study, challenges to the initial implementation of the epidermal by pharmaceutical industry. This study indicates that growth factor receptor (EGFR) mutation test, which is predictive funding has a substantial impact on the uptake of EGFR of better outcomes from first-line EGFR tyrosine kinase inhibitor test, therefore a national strategy on securing resources to treatments compared with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Loading next page...
 
/lp/wolters-kluwer-health/in-this-issue-YZokY5T8fX

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2013 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e3182a69c3e
Publisher site
See Article on Publisher Site

Abstract

OPTOMETRY AND VISION SCIENCE Copyright © 2013 American Academy of Optometry • Challenges to and colleagues. Five pharmaceutical industry–funded Implementation of an laboratories across Canada were included in a validation Epidermal Growth Factor and quality control exercise for the EGFR test. Patients with Receptor Testing Strategy nonsquamous lung cancer were enrolled online, where basic for Non–Small-Cell Lung demographics and decision on gefinitib prescription were Cancer in a Publicly Funded Health Care recorded. Of the 2104 requests for EGFR mutation testing, System 84% were fulfilled, with a median turnaround time of 18 days. The majority of the requests were for adenocarcinoma and stage IV disease, 58% women, 41% light/never smokers, and 13.9% Asians. Among patients tested for EGFR mutation, 17% were prescribed with gefitinib. The number of tests requested each month dropped from 200–250 to 50–100 after the initial 12 months, funded In this study, challenges to the initial implementation of the epidermal by pharmaceutical industry. This study indicates that growth factor receptor (EGFR) mutation test, which is predictive funding has a substantial impact on the uptake of EGFR of better outcomes from first-line EGFR tyrosine kinase inhibitor test, therefore a national strategy on securing resources to treatments compared with

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Sep 1, 2013

There are no references for this article.